Covert intel from an embedded journalist
Keep this secret between us, but every March, STAT reporter Adam Feuerstein sneaks into the Cowen Healthcare Conference to hear investors and doctor-specialists critique approved and experimental drugs across nearly two dozen disease areas.
It's a novel setup, as investor conferences go. And the experts' honest takes offer a helpful sentiment check on biotech and pharma companies.
Adam just returned from this year’s Cowen confab, and he’s sharing what he learned about Biomarin, Bluebird Bio, Sage Therapeutics, and a few other biotechs.
Read more.
No hay comentarios:
Publicar un comentario